Genome-wide Association Study

Genome-wide Association Study to Predict Treatment Response for Chemotherapy in Esophageal Squamous Cell Carcinoma

Status

Withdrawn

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01498757

Enrollment

Registered

2011-12-23

Start date

2012-01-31

Completion date

2012-07-03

Last updated

2019-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Squamous Cell Carcinoma

Brief summary

To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histological confirmed esophageal squamous cell carcinoma * Patients treated with Taxane or 5-FU or platinum based chemotherapy. * provision of a signed written informed consent.

Exclusion criteria

* patients not signed written informed consent. * patient unacceptable for study in the judgement of the investigator.

Design outcomes

Primary

Measure	Time frame	Description
Biomarkers predictive	24months	Biomarkers predictive of clinical response to Taxane or 5-fluorouracil or platinum based chemotherapy.

Countries

South Korea

Outcome results